Edition:
United States

OncoMed Pharmaceuticals Inc (OMED.OQ)

OMED.OQ on NASDAQ Stock Exchange Global Select Market

7.64USD
12:00pm EST
Change (% chg)

$-0.40 (-4.98%)
Prev Close
$8.04
Open
$7.97
Day's High
$7.97
Day's Low
$7.59
Volume
20,569
Avg. Vol
65,824
52-wk High
$17.82
52-wk Low
$7.42

Latest Key Developments (Source: Significant Developments)

OncoMed announces year-end cash balance and 2017 outlook
Thursday, 5 Jan 2017 08:30am EST 

Oncomed Pharmaceuticals Inc : OncoMed announces year-end cash balance and 2017 outlook . Expects 2017 operating cash burn to be less than $100 million, before considering potential milestones/opt-ins . "Phase 2 clinical trial results for demcizumab and tarextumab are anticipated in first half of year" . "Oncomed could receive more than $170 million in total 2017 partner opt-in payments" .Expects to file an IND in first half of 2017 for Oncomed's wholly owned GITRL-FC (OMP-336B11) trimer program.  Full Article

BVF Inc reports 4.9 pct passive stake in Oncomed Pharmaceuticals - SEC filing
Friday, 26 Aug 2016 01:32pm EDT 

BVF Inc:BVF Inc reports 4.9 pct passive stake in Oncomed Pharmaceuticals as of Aug. 18, 2016 - SEC filing.  Full Article

Celgene reports 8.1 pct passive stake in Oncomed Pharmaceuticals
Wednesday, 24 Aug 2016 06:23am EDT 

Oncomed Pharmaceuticals :Celgene Corporation reports 8.1 pct passive stake in Oncomed Pharmaceuticals Inc as of August 23, 2016 - SEC filing.  Full Article

OncoMed Pharmaceuticals prices public offering of common stock
Thursday, 18 Aug 2016 08:00am EDT 

OncoMed Pharmaceuticals Inc : OncoMed Pharmaceuticals announces pricing of public offering of common stock .Says public offering of 5.50 million common shares priced at $10.00 per share.  Full Article

Oncomed Pharmaceuticals announces proposed public offering of common stock
Wednesday, 17 Aug 2016 04:07pm EDT 

Oncomed Pharmaceuticals Inc : Oncomed Pharmaceuticals announces proposed public offering of common stock .To use net proceeds from offering for general corporate purposes, increasing working capital, funding research development.  Full Article

Oncomed pharmaceuticals reports Q2 2016 financial results
Tuesday, 9 Aug 2016 04:05pm EDT 

Oncomed Pharmaceuticals Inc : Oncomed pharmaceuticals reports second quarter 2016 financial results .Q2 loss per share $0.91.  Full Article

OncoMed provides update on tarextumab Phase 2 Pancreatic Cancer ALPINE Trial
Monday, 25 Jan 2016 07:30am EST 

OncoMed Pharmaceuticals Inc:Announces an update on the Phase 2 ALPINE clinical trial following a pre-planned January 23 interim efficacy assessment of the clinical trial by an independent data safety monitoring board (DSMB).No unexpected safety findings emerged from its review.Says eighteen patients remain on study drug treatment (tarextumab or placebo) between 172 and 527 days.  Full Article

OncoMed completes enrollment of phase 2 alpine clinical trial of tarextumab in pancreatic cancer
Monday, 31 Aug 2015 08:30am EDT 

OncoMed:Says it has completed patient enrollment in its Phase 2 'ALPINE' clinical trial of tarextumab (anti-Notch2/3, OMP-59R5) for the treatment of pancreatic cancer more than eight months ahead of schedule.Says the ALPINE study enrolled 177 patients with advanced pancreatic cancer who had not received prior treatment.Says enrollment in the randomized, double-blinded, multi-center clinical study began in July 2014.  Full Article

OncoMed Presents Phase 1b Clinical Trial Data for Tarextumab in Small Cell Lung Cancer
Monday, 1 Jun 2015 09:00am EDT 

OncoMed:Presents phase 1b clinical trial data for tarextumab in small cell lung cancer at the 2015 asco annual meeting.Early data suggests patients whose tumors had high notch3 gene expression may achieve prolonged survival outcomes with tarextumab treatment.Says of 26 patients evaluable for radiographic recist response, 20 (77%) achieved partial responses.Of 26 patients evaluable for radiographic recist response, six achieved stable disease for clinical benefit rate of 100%.Says the combination of tarextumab with chemotherapy was well tolerated up to 15 mg/kg.  Full Article

OncoMed Pharmaceuticals Inc and Lilly Enter clinical supply agreement to evaluate combination of Demcizumab and Alimta (pemetrexed for injection) in lung cancer
Thursday, 2 Apr 2015 08:30am EDT 

OncoMed Pharmaceuticals Inc:Says it has entered into an agreement with Eli Lilly and Company.Demcizumab, OncoMed's anti-DLL4 antibody, is being tested in combination with Lilly's Alimta (pemetrexed for injection) and carboplatin for the treatment of first-line advanced non-small cell lung cancer (NSCLC).Under terms of this agreement, Lilly will provide clinical supply of Alimta for OncoMed's ongoing Phase 2 DENALI trial.  Full Article

BRIEF-Oncomed Pharmaceuticals reports Q3 financial results

* "We expect to file inds for two immuno-oncology programs in late 2016 though first half of 2017"